Cargando…

Age-Dependent Pre-Vaccination Immunity Affects the Immunogenicity of Varicella Zoster Vaccination in Middle-aged Adults

BACKGROUND: Prevention of infectious diseases is of high priority in the rapidly aging population. Unfortunately, vaccine responses in the elderly are frequently diminished. Timely vaccination of middle-aged adults might improve the immune responses to vaccines, although knowledge on pathogen-specif...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Heiden, Marieke, de Rond, Lia G. H., van Zelm, Menno C., Berbers, Guy A. M., Boots, Annemieke M. H., Buisman, Anne-Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787056/
https://www.ncbi.nlm.nih.gov/pubmed/29410671
http://dx.doi.org/10.3389/fimmu.2018.00046
_version_ 1783295853077725184
author van der Heiden, Marieke
de Rond, Lia G. H.
van Zelm, Menno C.
Berbers, Guy A. M.
Boots, Annemieke M. H.
Buisman, Anne-Marie
author_facet van der Heiden, Marieke
de Rond, Lia G. H.
van Zelm, Menno C.
Berbers, Guy A. M.
Boots, Annemieke M. H.
Buisman, Anne-Marie
author_sort van der Heiden, Marieke
collection PubMed
description BACKGROUND: Prevention of infectious diseases is of high priority in the rapidly aging population. Unfortunately, vaccine responses in the elderly are frequently diminished. Timely vaccination of middle-aged adults might improve the immune responses to vaccines, although knowledge on pathogen-specific immune responses and factors affecting these responses, in middle-aged adults is currently limited. We thus investigated the immune responses after vaccination with Zostavax consisting of live-attenuated varicella zoster virus (VZV). METHODS: Blood samples were taken pre-, 14 days, 28 days, and 1 year after a primary VZV vaccination (Zostavax) at middle age (N = 53, 50–65 years of age). VZV-specific IFNγ-producing cells were measured by ELISpot, activated T-cells by flow cytometry, antibody levels and cytokine responses by fluorescent bead-based multiplex immunoassays, and whole blood cellular kinetics by TruCOUNT analysis. RESULTS: Robust short-term enhancement of the VZV-specific IFNγ-producing cell numbers was observed post-vaccination in the middle-aged adults. Remarkably, long-term enhancement of VZV-specific IFNγ-producing cell numbers was induced only in participants with low numbers of VZV-specific pre-vaccination IFNγ-producing cells, who were significantly older. These participants also showed enhancement of VZV-specific activated CD4 T-cells, contrary to “exhausted” VZV-specific CD8 T-cells in participants with high numbers of VZV-specific pre-vaccination IFNγ-producing cells. Finally, a high CD4/CD8 T-cell ratio was associated with low numbers of pre-vaccination VZV-specific IFNγ-producing cells. CONCLUSION: These results suggest that adults in their early sixties, who showed a high CD4/CD8 T-cell ratio and low numbers of VZV-specific IFNγ-producing cells, benefit from VZV vaccination. This provides important knowledge on factors affecting VZV-specific immune responses in middle-aged adults as well as for strategies to strengthen immunity before reaching old age.
format Online
Article
Text
id pubmed-5787056
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-57870562018-02-06 Age-Dependent Pre-Vaccination Immunity Affects the Immunogenicity of Varicella Zoster Vaccination in Middle-aged Adults van der Heiden, Marieke de Rond, Lia G. H. van Zelm, Menno C. Berbers, Guy A. M. Boots, Annemieke M. H. Buisman, Anne-Marie Front Immunol Immunology BACKGROUND: Prevention of infectious diseases is of high priority in the rapidly aging population. Unfortunately, vaccine responses in the elderly are frequently diminished. Timely vaccination of middle-aged adults might improve the immune responses to vaccines, although knowledge on pathogen-specific immune responses and factors affecting these responses, in middle-aged adults is currently limited. We thus investigated the immune responses after vaccination with Zostavax consisting of live-attenuated varicella zoster virus (VZV). METHODS: Blood samples were taken pre-, 14 days, 28 days, and 1 year after a primary VZV vaccination (Zostavax) at middle age (N = 53, 50–65 years of age). VZV-specific IFNγ-producing cells were measured by ELISpot, activated T-cells by flow cytometry, antibody levels and cytokine responses by fluorescent bead-based multiplex immunoassays, and whole blood cellular kinetics by TruCOUNT analysis. RESULTS: Robust short-term enhancement of the VZV-specific IFNγ-producing cell numbers was observed post-vaccination in the middle-aged adults. Remarkably, long-term enhancement of VZV-specific IFNγ-producing cell numbers was induced only in participants with low numbers of VZV-specific pre-vaccination IFNγ-producing cells, who were significantly older. These participants also showed enhancement of VZV-specific activated CD4 T-cells, contrary to “exhausted” VZV-specific CD8 T-cells in participants with high numbers of VZV-specific pre-vaccination IFNγ-producing cells. Finally, a high CD4/CD8 T-cell ratio was associated with low numbers of pre-vaccination VZV-specific IFNγ-producing cells. CONCLUSION: These results suggest that adults in their early sixties, who showed a high CD4/CD8 T-cell ratio and low numbers of VZV-specific IFNγ-producing cells, benefit from VZV vaccination. This provides important knowledge on factors affecting VZV-specific immune responses in middle-aged adults as well as for strategies to strengthen immunity before reaching old age. Frontiers Media S.A. 2018-01-23 /pmc/articles/PMC5787056/ /pubmed/29410671 http://dx.doi.org/10.3389/fimmu.2018.00046 Text en Copyright © 2018 van der Heiden, de Rond, van Zelm, Berbers, Boots and Buisman. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
van der Heiden, Marieke
de Rond, Lia G. H.
van Zelm, Menno C.
Berbers, Guy A. M.
Boots, Annemieke M. H.
Buisman, Anne-Marie
Age-Dependent Pre-Vaccination Immunity Affects the Immunogenicity of Varicella Zoster Vaccination in Middle-aged Adults
title Age-Dependent Pre-Vaccination Immunity Affects the Immunogenicity of Varicella Zoster Vaccination in Middle-aged Adults
title_full Age-Dependent Pre-Vaccination Immunity Affects the Immunogenicity of Varicella Zoster Vaccination in Middle-aged Adults
title_fullStr Age-Dependent Pre-Vaccination Immunity Affects the Immunogenicity of Varicella Zoster Vaccination in Middle-aged Adults
title_full_unstemmed Age-Dependent Pre-Vaccination Immunity Affects the Immunogenicity of Varicella Zoster Vaccination in Middle-aged Adults
title_short Age-Dependent Pre-Vaccination Immunity Affects the Immunogenicity of Varicella Zoster Vaccination in Middle-aged Adults
title_sort age-dependent pre-vaccination immunity affects the immunogenicity of varicella zoster vaccination in middle-aged adults
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787056/
https://www.ncbi.nlm.nih.gov/pubmed/29410671
http://dx.doi.org/10.3389/fimmu.2018.00046
work_keys_str_mv AT vanderheidenmarieke agedependentprevaccinationimmunityaffectstheimmunogenicityofvaricellazostervaccinationinmiddleagedadults
AT derondliagh agedependentprevaccinationimmunityaffectstheimmunogenicityofvaricellazostervaccinationinmiddleagedadults
AT vanzelmmennoc agedependentprevaccinationimmunityaffectstheimmunogenicityofvaricellazostervaccinationinmiddleagedadults
AT berbersguyam agedependentprevaccinationimmunityaffectstheimmunogenicityofvaricellazostervaccinationinmiddleagedadults
AT bootsannemiekemh agedependentprevaccinationimmunityaffectstheimmunogenicityofvaricellazostervaccinationinmiddleagedadults
AT buismanannemarie agedependentprevaccinationimmunityaffectstheimmunogenicityofvaricellazostervaccinationinmiddleagedadults